Get quick answers to your questions about the article from our AI researcher chatbot
{'id': 'https://openalex.org/W2081797247', 'doi': 'https://doi.org/10.1200/jco.2003.10.039', 'title': 'Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma', 'display_name': 'Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma', 'publication_year': 2003, 'publication_date': '2003-07-01', 'ids': {'openalex': 'https://openalex.org/W2081797247', 'doi': 'https://doi.org/10.1200/jco.2003.10.039', 'mag': '2081797247', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/12829675'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1200/jco.2003.10.039', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S15137598', 'display_name': 'Journal of Clinical Oncology', 'issn_l': '0732-183X', 'issn': ['0732-183X', '1527-7755'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref', 'pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5070212769', 'display_name': 'Sarah Danson', 'orcid': 'https://orcid.org/0000-0002-3593-2890'}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'S. Danson', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5069095893', 'display_name': 'Paul Lorigan', 'orcid': 'https://orcid.org/0000-0002-8875-2164'}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'P. Lorigan', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5009056091', 'display_name': 'Ana Arance', 'orcid': 'https://orcid.org/0000-0003-2896-1957'}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'A. Arance', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5032801379', 'display_name': 'Andrew R. Clamp', 'orcid': 'https://orcid.org/0000-0002-4200-0186'}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'A. Clamp', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5055792960', 'display_name': 'Malcolm Ranson', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'M. Ranson', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5023597127', 'display_name': 'Jackie Hodgetts', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'J. Hodgetts', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5041488297', 'display_name': 'L Lomax', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'L. Lomax', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5025124724', 'display_name': 'Linda Ashcroft', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'L. Ashcroft', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5086174841', 'display_name': 'N. Thatcher', 'orcid': 'https://orcid.org/0000-0002-0387-5895'}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'N. Thatcher', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5051430596', 'display_name': 'Mark R. Middleton', 'orcid': 'https://orcid.org/0000-0003-0167-1685'}, 'institutions': [{'id': 'https://openalex.org/I2802720485', 'display_name': 'Weston Park Cancer Centre', 'ror': 'https://ror.org/042gs1a72', 'country_code': 'GB', 'type': 'healthcare', 'lineage': ['https://openalex.org/I2802720485', 'https://openalex.org/I4210102902']}], 'countries': ['GB'], 'is_corresponding': False, 'raw_author_name': 'M.R. Middleton', 'raw_affiliation_strings': ['From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.'], 'affiliations': [{'raw_affiliation_string': 'From the Christie Hospital, Manchester; and Weston Park Hospital, Sheffield, United Kingdom.', 'institution_ids': ['https://openalex.org/I2802720485']}]}], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 5.117, 'has_fulltext': True, 'fulltext_origin': 'ngrams', 'cited_by_count': 107, 'citation_normalized_percentile': {'value': 0.822086, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 96, 'max': 97}, 'biblio': {'volume': '21', 'issue': '13', 'first_page': '2551', 'last_page': '2557'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11533', 'display_name': 'Mammalian MAP Kinase Signaling Pathways', 'score': 0.9996, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11533', 'display_name': 'Mammalian MAP Kinase Signaling Pathways', 'score': 0.9996, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10649', 'display_name': 'Diagnosis and Treatment of Multiple Myeloma', 'score': 0.9994, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T10755', 'display_name': 'HER2 Signaling in Breast Cancer Treatment', 'score': 0.9943, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/temozolomide', 'display_name': 'Temozolomide', 'score': 0.9820497}, {'id': 'https://openalex.org/keywords/dacarbazine', 'display_name': 'Dacarbazine', 'score': 0.86169344}, {'id': 'https://openalex.org/keywords/melanoma', 'display_name': 'Melanoma', 'score': 0.560964}, {'id': 'https://openalex.org/keywords/tolerability', 'display_name': 'Tolerability', 'score': 0.55155414}, {'id': 'https://openalex.org/keywords/interferon-alfa', 'display_name': 'Interferon alfa', 'score': 0.43827543}], 'concepts': [{'id': 'https://openalex.org/C2777389519', 'wikidata': 'https://www.wikidata.org/wiki/Q425088', 'display_name': 'Temozolomide', 'level': 3, 'score': 0.9820497}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.90314543}, {'id': 'https://openalex.org/C2780964509', 'wikidata': 'https://www.wikidata.org/wiki/Q416975', 'display_name': 'Dacarbazine', 'level': 3, 'score': 0.86169344}, {'id': 'https://openalex.org/C2779609412', 'wikidata': 'https://www.wikidata.org/wiki/Q203174', 'display_name': 'Thalidomide', 'level': 3, 'score': 0.62077045}, {'id': 'https://openalex.org/C2777658100', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Melanoma', 'level': 2, 'score': 0.5828964}, {'id': 'https://openalex.org/C31760486', 'wikidata': 'https://www.wikidata.org/wiki/Q7180990', 'display_name': 'Phases of clinical research', 'level': 3, 'score': 0.55229825}, {'id': 'https://openalex.org/C2778375690', 'wikidata': 'https://www.wikidata.org/wiki/Q7814214', 'display_name': 'Tolerability', 'level': 3, 'score': 0.55155414}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.5174363}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.50672084}, {'id': 'https://openalex.org/C2909179924', 'wikidata': 'https://www.wikidata.org/wiki/Q6046488', 'display_name': 'Alpha interferon', 'level': 3, 'score': 0.46782392}, {'id': 'https://openalex.org/C2781228144', 'wikidata': 'https://www.wikidata.org/wiki/Q6046441', 'display_name': 'Interferon alfa', 'level': 4, 'score': 0.43827543}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.43066758}, {'id': 'https://openalex.org/C90924648', 'wikidata': 'https://www.wikidata.org/wiki/Q120569', 'display_name': 'Gastroenterology', 'level': 1, 'score': 0.32998332}, {'id': 'https://openalex.org/C141071460', 'wikidata': 'https://www.wikidata.org/wiki/Q40821', 'display_name': 'Surgery', 'level': 1, 'score': 0.32457986}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.32331628}, {'id': 'https://openalex.org/C197934379', 'wikidata': 'https://www.wikidata.org/wiki/Q2047938', 'display_name': 'Adverse effect', 'level': 2, 'score': 0.279557}, {'id': 'https://openalex.org/C2776178377', 'wikidata': 'https://www.wikidata.org/wiki/Q188269', 'display_name': 'Interferon', 'level': 2, 'score': 0.23887879}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.22374403}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.13746345}, {'id': 'https://openalex.org/C203014093', 'wikidata': 'https://www.wikidata.org/wiki/Q101929', 'display_name': 'Immunology', 'level': 1, 'score': 0.13381827}, {'id': 'https://openalex.org/C2776364478', 'wikidata': 'https://www.wikidata.org/wiki/Q467635', 'display_name': 'Multiple myeloma', 'level': 2, 'score': 0.085633814}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.07732159}], 'mesh': [{'descriptor_ui': 'D000971', 'descriptor_name': 'Antineoplastic Combined Chemotherapy Protocols', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D003606', 'descriptor_name': 'Dacarbazine', 'qualifier_ui': 'Q000031', 'qualifier_name': 'analogs & derivatives', 'is_major_topic': True}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D009362', 'descriptor_name': 'Neoplasm Metastasis', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': True}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D000293', 'descriptor_name': 'Adolescent', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000328', 'descriptor_name': 'Adult', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000368', 'descriptor_name': 'Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000369', 'descriptor_name': 'Aged, 80 and over', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000971', 'descriptor_name': 'Antineoplastic Combined Chemotherapy Protocols', 'qualifier_ui': 'Q000009', 'qualifier_name': 'adverse effects', 'is_major_topic': False}, {'descriptor_ui': 'D000971', 'descriptor_name': 'Antineoplastic Combined Chemotherapy Protocols', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D003606', 'descriptor_name': 'Dacarbazine', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D003606', 'descriptor_name': 'Dacarbazine', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D018450', 'descriptor_name': 'Disease Progression', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D004334', 'descriptor_name': 'Drug Administration Schedule', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D005260', 'descriptor_name': 'Female', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007262', 'descriptor_name': 'Infusions, Intravenous', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D007279', 'descriptor_name': 'Injections, Subcutaneous', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077190', 'descriptor_name': 'Interferon alpha-2', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D016898', 'descriptor_name': 'Interferon-alpha', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D016898', 'descriptor_name': 'Interferon-alpha', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D008545', 'descriptor_name': 'Melanoma', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011994', 'descriptor_name': 'Recombinant Proteins', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': 'Q000473', 'qualifier_name': 'pathology', 'is_major_topic': False}, {'descriptor_ui': 'D012878', 'descriptor_name': 'Skin Neoplasms', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013534', 'descriptor_name': 'Survival', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000077204', 'descriptor_name': 'Temozolomide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1200/jco.2003.10.039', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S15137598', 'display_name': 'Journal of Clinical Oncology', 'issn_l': '0732-183X', 'issn': ['0732-183X', '1527-7755'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/12829675', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.74, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 26, 'referenced_works': ['https://openalex.org/W115311864', 'https://openalex.org/W1489896780', 'https://openalex.org/W1752324982', 'https://openalex.org/W1835101589', 'https://openalex.org/W1861898234', 'https://openalex.org/W1879616740', 'https://openalex.org/W1917632054', 'https://openalex.org/W1969331658', 'https://openalex.org/W1982798294', 'https://openalex.org/W1985147506', 'https://openalex.org/W1990159395', 'https://openalex.org/W2002288639', 'https://openalex.org/W2041332808', 'https://openalex.org/W2042774683', 'https://openalex.org/W2055057230', 'https://openalex.org/W2063324830', 'https://openalex.org/W2068306614', 'https://openalex.org/W2079786467', 'https://openalex.org/W2107018012', 'https://openalex.org/W2110429401', 'https://openalex.org/W2119925221', 'https://openalex.org/W2136790479', 'https://openalex.org/W2245369264', 'https://openalex.org/W2397230219', 'https://openalex.org/W2413740398', 'https://openalex.org/W4249905861'], 'related_works': ['https://openalex.org/W775998430', 'https://openalex.org/W3158265742', 'https://openalex.org/W2409032034', 'https://openalex.org/W2399057994', 'https://openalex.org/W2397644467', 'https://openalex.org/W2157027442', 'https://openalex.org/W2104788624', 'https://openalex.org/W2081797247', 'https://openalex.org/W1983403018', 'https://openalex.org/W1982193912'], 'abstract_inverted_index': {'Purpose:': [0], 'Temozolomide': [1], 'is': [2, 19, 23], 'an': [3], 'imidazotetrazine': [4], 'with': [5, 38, 43, 77, 88, 257, 270], 'a': [6, 24, 51, 135], 'mechanism': [7], 'of': [8, 56, 72, 102, 210, 264, 280], 'action': [9], 'similar': [10, 246], 'to': [11, 64, 94, 97, 122, 146, 155, 164, 217, 226, 235], 'dacarbazine': [12], 'and': [13, 22, 29, 45, 70, 82, 189, 194, 200, 230, 282], 'equivalent': [14], 'activity': [15], 'in': [16, 50, 75, 208, 247], 'melanoma.': [17, 80], 'It': [18], 'well': [20, 171], 'tolerated': [21], 'candidate': [25], 'for': [26, 110, 119, 173, 182, 187, 192, 251, 288], 'combination': [27, 279], 'chemotherapy': [28], 'schedule': [30], 'manipulation.': [31], 'In': [32], 'this': [33, 57], 'study,': [34], 'we': [35, 46], 'combined': [36], 'temozolomide': [37, 48, 103, 114, 138, 281], 'interferon': [39, 125], 'alfa-2b': [40, 126], 'and,': [41], 'separately,': [42], 'thalidomide,': [44], 'administered': [47], 'alone': [49], 'compressed': [52], 'schedule.': [53], 'The': [54, 167], 'objectives': [55], 'randomized': [58], 'phase': [59], 'II,': [60], 'two-center': [61], 'study': [62], 'were': [63, 91, 170, 197, 245, 261], 'determine': [65], 'response': [66], 'rates,': [67], 'overall': [68], 'survival,': [69], 'tolerability': [71], 'the': [73, 274, 278, 285], 'regimens': [74, 276], 'patients': [76, 87, 211], 'advanced': [78], 'metastatic': [79, 89], 'Patients': [81], 'Methods:': [83], 'One': [84], 'hundred': [85], 'eighty-one': [86], 'melanoma': [90], 'randomly': [92], 'assigned': [93], 'receive': [95], 'up': [96], 'six': [98], '4-weekly': [99], 'cycles': [100], 'consisting': [101], '200': [104, 115, 147], 'mg/m': [105, 116, 140, 148], '2': [106, 117, 141, 149], 'every': [107], '8': [108], 'hours': [109], 'five': [111], 'doses,': [112], 'or': [113, 137, 204, 241, 267], 'daily': [118, 151, 161], 'days': [120, 153, 162], '1': [121, 154, 163], '5': [123, 127, 156], 'plus': [124, 157], 'MU': [128], '(million': [129], 'International': [130], 'Units)': [131], 'subcutaneously': [132], 'three': [133, 275], 'times': [134], 'week,': [136], '150': [139], '(increased': [142], 'after': [143], 'one': [144], 'cycle': [145], ')': [150], 'on': [152], 'thalidomide': [158, 283], '100': [159], 'mg': [160], '28.': [165], 'Results:': [166], 'treatment': [168], 'arms': [169], 'balanced': [172], 'known': [174], 'prognostic': [175], 'factors.': [176], 'Median': [177], 'survival': [178], 'was': [179, 254], '5.3': [180], 'months': [181, 186, 191], '8-hourly': [183, 220, 258], 'temozolomide,': [184, 221], '7.7': [185], 'temozolomide/interferon,': [188, 229], '7.3': [190], 'temozolomide/thalidomide;': [193], '1-year': [195], 'survivals': [196], '18%,': [198], '26%,': [199], '24%,': [201], 'respectively.': [202], 'Response': [203], 'disease': [205], 'stabilization': [206], 'occurred': [207], '20%': [209], '(95%': [212, 223, 232], 'confidence': [213], 'interval': [214], '[CI],': [215], '10%': [216], '33%)': [218, 227], 'given': [219, 228, 237], '21%': [222], 'CI,': [224, 233], '12%': [225], '25%': [231], '15%': [234], '38%)': [236], 'temozolomide/thalidomide.': [238, 271], 'Grade': [239], '3': [240, 266], '4': [242, 268], 'nonhematologic': [243], 'toxicities': [244], 'each': [248], 'arm': [249], 'except': [250], 'infection,': [252], 'which': [253], 'more': [255], 'frequent': [256], 'temozolomide.': [259], 'There': [260], 'fewer': [262], 'instances': [263], 'grade': [265], 'myelotoxicity': [269], 'Conclusion:': [272], 'Of': [273], 'tested,': [277], 'seems': [284], 'most': [286], 'promising': [287], 'future': [289], 'study.': [290]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2081797247', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2020, 'cited_by_count': 1}, {'year': 2019, 'cited_by_count': 1}, {'year': 2018, 'cited_by_count': 3}, {'year': 2017, 'cited_by_count': 2}, {'year': 2016, 'cited_by_count': 1}, {'year': 2015, 'cited_by_count': 3}, {'year': 2013, 'cited_by_count': 5}, {'year': 2012, 'cited_by_count': 2}], 'updated_date': '2024-08-13T14:43:14.729167', 'created_date': '2016-06-24'}